News | December 14, 2025
Biocon Biologics signs settlement and lcense agreement to commercialize biosimilar Aflibercept
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The product will be marketed by Dr. Reddy's Laboratories Inc.
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The new site marks the company’s first operation in the region
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Subscribe To Our Newsletter & Stay Updated
